Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$153.12 - $183.64 $459,360 - $550,920
3,000 Added 17.65%
20,000 $3.67 Million
Q1 2024

May 15, 2024

SELL
$108.01 - $179.35 $2.48 Million - $4.13 Million
-23,000 Reduced 57.5%
17,000 $3.02 Million
Q4 2023

Feb 14, 2024

SELL
$96.0 - $128.29 $259,200 - $346,383
-2,700 Reduced 6.32%
40,000 $4.96 Million
Q3 2023

Nov 14, 2023

BUY
$108.51 - $130.22 $2.46 Million - $2.96 Million
22,700 Added 113.5%
42,700 $4.95 Million
Q2 2023

Aug 14, 2023

BUY
$78.48 - $130.32 $1.57 Million - $2.61 Million
20,000 New
20,000 $2.35 Million
Q1 2022

May 13, 2022

SELL
$51.99 - $72.11 $2.14 Million - $2.97 Million
-41,200 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$39.81 - $88.24 $1.64 Million - $3.64 Million
41,200 New
41,200 $2.88 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.07B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.